Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2026 | Optimizing frontline therapy selection to prevent resistance in CML

Jorge Cortes • 10 Sep 2026
SOHO 2026
Chronic Myeloid Leukemia Leukemia

Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses the misconception that the most effective available therapies should be reserved for later lines of treatment in chronic myeloid leukemia (CML). He highlights evidence that resistance and subsequent treatment switches can affect long-term survival, emphasizing the importance of selecting the most appropriate treatment from the outset. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jorge Cortes

Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Managing patients with CML and additional genetic abnormalities
1:34
Managing patients with CML and additional genetic abnormalities
Jorge Cortes • 10 Sep 2026
Where does the treatment landscape for managing frontline CML currently stand?
1:44
Where does the treatment landscape for managing frontline CML currently stand?
Jorge Cortes • 10 Sep 2026
Consensus recommendations for relapsed/refractory IDH1-mutated AML treatment
1:37
Consensus recommendations for relapsed/refractory IDH1-mutated AML treatment
Jorge Cortes • 12 Jun 2026

Related Videos

Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
2:01
Understanding the risks of lymphoproliferative disorders following CAR T-cell therapy
Michael Jain • 11 Sep 2026
Incorporating patient goals into frontline TKI selection in CML
2:17
Incorporating patient goals into frontline TKI selection in CML
Jorge Cortes • 10 Sep 2026
Integrating molecular testing into frontline treatment decisions in CLL
2:11
Integrating molecular testing into frontline treatment decisions in CLL
Kerry Rogers • 10 Sep 2026
Optimizing supportive care after completion of CLL treatment
1:16
Optimizing supportive care after completion of CLL treatment
Kerry Rogers • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals